Search Results
Your search for Blood matches 4668 pages
Showing 301 - 350Effect of Exercise on Symptom Burden and Quality of Life in Patients With Metastatic Breast Cancer
Taking part in an exercise program may improve pain, fatigue, and quality of life in patients with metastatic breast cancer, according to recent findings presented by Hiensch et al at the 2024 European Breast Cancer Conference (EBCC; Abstract 1). Background “Although there’s been quite a lot of...
Incidence of Secondary T-Cell Malignancies Following CAR T-Cell Therapy
Investigators have found that second primary malignancies following chimeric antigen receptor (CAR) T-cell therapy were reported in 4.3% of CAR T-cell therapy adverse event reports submitted to the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System, with T-cell malignancies...
Fruquintinib Plus Paclitaxel Under Study as Second-Line Treatment of Gastroesophageal Cancer
The combination of the small molecule inhibitor of VEGFR fruquintinib and the chemotherapy paclitaxel presents a potential new second-line treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to data presented during the ASCO Plenary Series: February...
CAR T-Cell Therapy Complications: Comparison of Three Testing Modalities
Magnetic resonance imaging (MRI) and lumbar puncture may not always be necessary for diagnosing and managing a serious neurologic complication associated with chimeric antigen receptor (CAR) T-cell therapy, according to a new study published by Mauget et al in Blood Advances. Findings further...
Mantle Cell Lymphoma: Front-Line Therapy
“The practice of medicine is an art, not a trade….” —Sir William Osler Mantle cell lymphoma (MCL) accounts for approximately 5% to 7% of all lymphomas; the median age of patients with MCL is between 60 and 70 years. This lymphoma is generally considered incurable. Median survival in retrospective...
Strategies for Cardiovascular Risk Mitigation and Monitoring in Patients With CLL
With a 5-year overall survival of close to 90% in chronic lymphocytic leukemia (CLL), there have been large treatment shifts over the past decade in this disease, which now includes “more disciplines than it did before,” commented medical oncologist Danielle Shafer, DO, of Inova Schar Cancer...
Risks of Cardiovascular Disease in Patients Receiving Therapies for Lung Cancer
Managing patients with lung cancer in the current era of an increasing array of systemic treatments has become a complex balancing act of trying to improve outcomes and survival from a cancer perspective while taking the necessary treatment and monitoring steps for cardioprotection. With few...
Avelumab Plus Axitinib in Mismatch Repair–Proficient Recurrent or Persistent Endometrial Cancer
The combination of avelumab and axitinib may be effective in patients with mismatch repair–proficient recurrent or persistent endometrial cancer, according to new findings presented by Lee et al at the Society of Gynecologic Oncology’s (SGO) 2024 Annual Meeting on Women’s Cancer. Background...
Performance of cfDNA Blood-Based Test for Colorectal Cancer Screening
In the ECLIPSE study—reported in The New England Journal of Medicine—Chung et al found that a cell-free DNA (cfDNA) blood-based test had high sensitivity for colorectal cancer and high specificity for advanced neoplasia in colorectal cancer screening compared with colonoscopy. Study Details The...
Accelerated Approval Granted to First CAR T-Cell Therapy for Relapsed or Refractory CLL/SLL
On March 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lisocabtagene maraleucel (Breyanzi), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small...
Worsening Metabolic Syndrome May Increase Cancer Risk
Investigators may have identified a heightened risk of various types of cancers among patients with persistent and worsening metabolic syndrome, according to a recent study published by Deng et al in Cancer. Background Metabolic syndrome encompasses conditions such as high blood pressure, elevated...
Expert Point of View: Michael Crump, MD
Michael Crump, MD, of the Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, Toronto, expressed some concerns about the study presented by Shadman et al in patients with large B-cell lymphoma (LBCL). “These data should be interpreted with caution. The patient...
Should You Reconsider Transplant for Relapsed Large B-Cell Lymphoma in Complete Remission?
For patients with relapsed large B-cell lymphoma (LBCL) in complete remission, outcomes were better after autologous stem cell transplantation (ASCT) than with chimeric antigen receptor (CAR) T-cell therapy in a retrospective analysis of a large database presented at the 2023 American Society of...
FDA Approves Inotuzumab Ozogamicin for Pediatric Patients With ALL
On March 6, the U.S. Food and Drug Administration (FDA) approved the CD22-targeted antibody-drug conjugate inotuzumab ozogamicin (Besponsa) for pediatric patients aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). Study WI203581...
Circulating Leukocyte Subsets After Breast Cancer Diagnosis and Treatment
In an analysis reported in JAMA Network Open, Jacob K. Kresovich, PhD, and colleagues identified differences in circulating leukocyte subsets between women who were diagnosed and treated for breast cancer vs those not diagnosed with breast cancer. As stated by the investigators: “Changes in...
U.S. Individuals With Incarceration History May Have Lower Likelihood of Undergoing Cancer Screenings
Investigators have found that U.S. individuals with a history of incarceration may have worse access to and receipt of breast cancer and colorectal cancer screenings compared with those without a history of incarceration, according to a recent study published by Zhao et al in JAMA Health Forum....
COVID-19 Risk in Pediatric Patients Receiving Treatment for Acute Lymphoblastic Leukemia or Lymphoma
In a retrospective case series reported in JAMA Network Open, Hashmi et al found that more than one-third of pediatric patients receiving treatment for newly diagnosed acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LL) developed COVID-19 infection during a recent 2-year period. Study...
Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
The chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel may offer benefit in patients with multiple myeloma who experienced disease progression or relapse following initial therapy, according to new findings presented by Hillengass et al at the 2024 Tandem Meetings:...
Exploring the Role of Intravenous Mistletoe Extract in Treating Metastatic Solid Tumors
Guest Editor’s Note: The use of mistletoe extract to support systemic therapy and improve quality of life for patients with cancer, though common, remains controversial. Promising results have been reported, but largely in trials that were not placebo-controlled nor properly randomized. In this...
Preventing Cancer Should Not Mean Sacrificing Quality of Life
My family first suspected we might have inherited the BRCA1/2 gene mutation after my father was diagnosed with his third cancer, colorectal cancer, following multiple bouts of squamous cell carcinoma and basal cell carcinoma beginning in his 30s and later prostate cancer. But the high risk of...
Understanding Risk Stratification in Monoclonal Gammopathy of Undetermined Significance
About 4 years ago, I [Jo Cavallo] wrote about the death of my brother Dom from multiple myeloma in 2011 and my subsequent enrollment in the PROMISE trial (ClinicalTrials.gov identifier NCT03689595). My goal for enrolling in the study was twofold: to honor Dom and others with the cancer and to make ...
Prophylactic Oral Vancomycin May Prevent C Difficile Infections, Raise Risk of Gram-Negative Bacteremia in Stem Cell Transplant Recipients
Preventive use of the oral antibiotic vancomycin may be effective at reducing the risk of Clostridioides difficile infections but may increase the risk of gram-negative bacteremia in stem cell transplant recipients, according to new findings presented by Vartanov et al at the 2024 Tandem Meetings:...
Rapid Guideline Update on Radiotracers for Determining Radioligand Treatment Eligibility in Metastatic Castration-Resistant Prostate Cancer
ASCO has released a guideline rapid recommendation update addressing radiotracers used for prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) diagnostic imaging for selecting patients with metastatic castration-resistant prostate cancer (mCRPC) to receive...
Perioperative Tislelizumab Plus Chemotherapy in Resectable NSCLC
In patients with resectable non–small cell lung cancer (NSCLC), perioperative treatment with the checkpoint inhibitor tislelizumab plus platinum-doublet chemotherapy led to a statistically significant benefit in event-free survival and a favorable trend for overall survival, investigators for the...
FDA Approves Osimertinib With Chemotherapy for EGFR-Mutated NSCLC
On February 16, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso) with platinum-based chemotherapy for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an...
Venetoclax Plus Azacitidine Evaluated in High-Risk Myelodysplastic Syndromes
For the treatment of high-risk, treatment-naive myelodysplastic syndromes (MDS), the regimen of venetoclax plus azacitidine led to high response rates, durable responses, and encouraging overall survival, in a phase Ib study reported at the 2023 American Society of Hematology (ASH) Annual Meeting...
First-Line Ruxolitinib Combinations Boost Benefit Over Single Agent in Myelofibrosis
In two international phase III trials in myelofibrosis, drugs given in combination with the Janus kinase (JAK) inhibitor ruxolitinib in JAK inhibitor–naive patients significantly improved outcomes vs ruxolitinib alone. Both studies were presented at the 2023 American Society of Hematology Annual...
Study Finds Four-Drug Targeted Treatment Reduces Chemotherapy Requirement for Some in Large B-Cell Lymphoma
A four-drug targeted therapy regimen proved safe and effective as the first-line treatment of diffuse large B-cell lymphoma (DLBCL), achieving a 100% response rate after four cycles, researchers from The University of Texas MD Anderson Cancer Center, Houston, reported at the 2023 American Society...
Expert Point of View: Cynthia E. Dunbar, MD
In a press briefing at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, Cynthia E. Dunbar, MD, ASH Secretary and Chief of the Translational Stem Cell Biology Branch, Intramural Research Program of the National Heart, Lung, and Blood Institute, offered her thoughts on...
Highlights From the 2023 ASH Annual Meeting & Exposition
Hordes of classical and malignant hematologists returned to the tranquil city of San Diego for the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition this past December. The packed agenda lit the Gaslight District up with neuron-searing data, creating an environment for...
Expert Point of View: Michael Crump, MD
Michael Crump, MD, of the Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, Toronto, expressed some concerns about the study presented by Shadman et al in patients with large B-cell lymphoma (LBCL). “These data should be interpreted with caution. The patient...
Should You Reconsider Transplant for Relapsed Large B-Cell Lymphoma in Complete Remission?
For patients with relapsed large B-cell lymphoma (LBCL) in complete remission, outcomes were better after autologous stem cell transplantation (ASCT) than with chimeric antigen receptor (CAR) T-cell therapy in a retrospective analysis of a large database presented at the 2023 American Society of...
Expert Point of View: Peter Voorhees, MD
Peter Voorhees, MD, a multiple myeloma specialist at Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Durham, North Carolina, introduced the plenary presentation of the phase III IsKia trial by Gay et al and further commented on the study for The ASCO...
Expert Point of View: William G. Blum, MD and Mikkael Sekeres, MD, MS
Thoughts on the study by Othman et al were provided by William G. Blum, MD, Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine and Director of the Acute Leukemia Program at Winship Cancer Institute, and Mikkael Sekeres, MD, MS, Professor of...
In NPM1-Mutated AML, Benefit of Transplant Limited to Patients With Residual Disease
In patients with NPM1-mutated acute myeloid leukemia (AML), the presence of molecular measurable residual disease (MRD) in the peripheral blood following induction chemotherapy can aid decision-making about postremission therapy. More specifically, MRD status in the peripheral blood can identify...
PERSEUS: Daratumumab Regimen Significantly Improves Progression-Free Survival in Newly Diagnosed Multiple Myeloma
The addition of the CD38 monoclonal antibody daratumumab to a standard regimen for patients with newly diagnosed transplant-eligible multiple myeloma significantly prolonged progression-free survival vs standard treatment in the phase III PERSEUS trial. The study was reported as a late-breaking...
Sleep Apnea May Be Prevalent Among Patients With Cancer at High Risk of Congestive Heart Failure
Sleep apnea may be prevalent among patients who are at higher risk of developing congestive heart failure from cancer therapy, according to new findings presented by Das et al at the American College of Cardiology (ACC) Advancing the Cardiovascular Care of the Oncology Patient course. Background...
Novel Biomarker in Cancer Survivors May Be Linked to Higher Risk of Mortality
Elevated N-terminal pro–brain natriuretic peptide (NT-proBNP) levels may be associated with a higher risk of mortality among cancer survivors, according to a recent study published by Cao et al in the Journal of the National Cancer Institute. NT-proBNP—produced in response to the stretching of...
Shedding Light on Mechanisms Behind Fulvestrant Resistance in Advanced ER-Positive Breast Cancer
Researchers may have uncovered the factors contributing to hormone therapy resistance in some patients with advanced estrogen receptor (ER)-positive breast cancer, according to a recent study published by Kingston et al in Cancer Discovery. The findings may indicate drugs currently in development...
MRD Markers and Outcomes in Patients With MDS After Stem Cell Transplant
In a Scandinavian study reported in the Journal of Clinical Oncology, Tobiasson et al found that individual-patient measurable residual disease (MRD) could be assessed by next-generation sequencing (NGS) and droplet digital polymerase chain reaction (ddPCR) to predict outcomes in patients with...
Ephrin B2 Identified as Potential Therapeutic Target to Inhibit Multiple Myeloma Growth
Researchers have discovered that the ephrin B2 protein may drive the growth and development of multiple myeloma and uncovered that blocking part of the protein’s unique signaling pathway may inhibit progression of the disease, according to a recent study published by Sasine et al in Cancer...
Fruquintinib Plus Paclitaxel as Second-Line Treatment for Gastric or Gastroesophageal Junction Cancer
The combination of fruquintinib and paclitaxel is a potential new second-line treatment for patients with advanced gastric or gastroesophageal junction cancer, according to data presented during the ASCO Plenary Series: February 2024 Session (Abstract 438780). Results of the phase III FRUTIGA...
Antihypertensive Drug Combinations May Help Reduce Blood Pressure in Patients Receiving Ibrutinib
Combination therapy with two or more antihypertensive drugs may reduce blood pressure in patients receiving ibrutinib, according to a recent study published by Samples et al in Blood Advances. Background Ibrutinib was the first Bruton tyrosine kinase (BTK) inhibitor to receive U.S. Food and Drug...
BTK Degrader May Target Treatment Resistance in Patients With CLL
Researchers have identified a next-generation Bruton’s tyrosine kinase (BTK) degrader that could help patients with chronic lymphocytic leukemia (CLL) and related hematologic malignancies overcome treatment resistance, according to a recent study published by Montoya et al in Science. The findings...
Golidocitinib in Relapsed or Refractory Peripheral T-Cell Lymphoma
In a phase II trial (JACKPOT8 Part B) reported in The Lancet Oncology, Song et al found that the selective JAK1 tyrosine kinase inhibitor golidocitinib showed activity in patients with relapsed or refractory peripheral T-cell lymphoma. Study Details In the trial, 104 patients from sites in...
Blood Tests Could Help Predict Which Patients With Lymphoma May Respond Poorly to CAR T-Cell Therapy
Researchers may have uncovered a novel strategy to identify which patients may experience poorer outcomes from chimeric antigen receptor (CAR) T-cell therapy prior to treatment, according to a recent study published by Faramand et al in Blood Cancer Discovery. The findings indicate opportunities to ...
UCHL1 Protein: Potential Biomarker and Therapeutic Target in Neuroendocrine Carcinomas and Neuroblastoma?
Investigators have found that the protein UCHL1 may be used as a molecular biomarker for diagnosing patients with highly aggressive neuroendocrine carcinomas and neuroblastoma and predicting and monitoring responses to therapy, according to a study published by Liu et al in Cell Reports Medicine....
Colon Cancer Mortality Rates: Predictions Across the European Union and United Kingdom
Investigators discovered that overweight and obesity may be contributing to rising rates of colon cancer mortality in younger patients, according to a recent study published by Santucci et al in the Annals of Oncology. The findings represent the first time colon cancer mortality rates among younger ...
Potential Risk Factors for Postoperative Venous Thromboembolism in Lung Cancer Identified
Postoperative pulmonary embolism may be predictive of increased 30-day mortality, reintubation, and readmission rates in patients with lung cancer, according to recent findings presented by Axtell et al at The Society of Thoracic Surgeons (STS) Annual Meeting. Background Patients with lung cancer...
FDG PET/CT Imaging Performed After 1 Week of Immunotherapy May Predict Treatment Response in Patients With Advanced Melanoma
A prospective pilot study investigating the use of early fluorodeoxyglucose F-18 (FDG) positron-emission tomography/computed tomography (PET/CT) in patients with advanced melanoma has found that metabolic changes in melanoma metastases detected on early FDG PET/CT imaging are potentially predictive ...
